Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Pharmacokinetics of Lutikizumab Formulations in Healthy and Chinese Subjects
NCT06067568Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2023
- Primary completion
- Feb 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lutikizumab in hidradenitis suppurativa (HS) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Serum Concentration at Day 8, Time to Cmax at Day 8 and 5 more. Started Sep 2023; status: completed.
02
Drugs
lutikizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06067568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067568.